Allogene Therapeutics Inc [ALLO] stock prices are down -2.34% to $1.67 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ALLO shares have gain 23.70% over the last week, with a monthly amount glided 12.84%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Allogene Therapeutics Inc [NASDAQ: ALLO] stock has seen the most recent analyst activity on January 09, 2026, when Citizens JMP upgraded its rating to a Mkt Outperform but kept the price target unchanged to $5 for it. Previously, JP Morgan downgraded its rating to Underweight on October 10, 2025. On May 14, 2025, downgrade downgraded it’s rating to Mkt Perform. Citizens JMP upgraded its rating to a Mkt Outperform but stick to its price target of $5 on March 14, 2025. Piper Sandler started tracking with an Overweight rating for this stock on May 31, 2024, and assigned it a price target of $11. In a note dated January 05, 2024, JMP Securities downgraded an Mkt Perform rating on this stock.
The stock price of Allogene Therapeutics Inc [ALLO] has been fluctuating between $0.86 and $3.78 over the past year. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Allogene Therapeutics Inc [NASDAQ: ALLO] shares were valued at $1.67 at the most recent close of the market. An investor can expect a potential return of 1636.53% based on the average ALLO price forecast.
Analyzing the ALLO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.58 and Total Capital is -0.56. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Allogene Therapeutics Inc [NASDAQ:ALLO]’s Current Ratio is 8.19. As well, the Quick Ratio is 8.19, while the Cash Ratio is 1.19.
Transactions by insiders
Recent insider trading involved Beneski Benjamin Machinas, SVP, Chief Technical Officer, that happened on Nov 17 ’25 when 786.0 shares were sold. Officer, Beneski Benjamin Machinas completed a deal on Nov 17 ’25 to buy 786.0 shares. Meanwhile, CHIEF FINANCIAL OFFICER Parker Geoffrey M. sold 36744.0 shares on Oct 21 ’25.
